BioVector® R4.2 缺陷型小鼠 B 淋巴细胞株 BioVector® R4.2 Mutant Mouse B-Cell Lymphoma Line

第一部分：中文说明

一、 产品基本信息与详细特征描述

• 产品名称：BioVector® R4.2 缺陷型小鼠 B 淋巴细胞株

• 细胞株名称：R4.2

• 物种来源：小鼠 (Mouse, Mus musculus)

• 组织来源：B 细胞淋巴瘤 (B-cell lymphoma) 衍生株

• 细胞属性：淋巴标本样细胞 (Lymphoblast-like) / 悬浮生长 (Suspension)

• 生物安全级别：1级 (BSL-1)

• 详细特征描述：BioVector® R4.2 是一种在免疫学、细胞生物学及抗原提呈机制研究中具有重要地位的特异性突变缺陷型小鼠 B 淋巴细胞株。该细胞系源自经化学或物理诱变筛选的 B 细胞淋巴瘤细胞（通常与大名鼎鼎的宿主杂交瘤或淋巴瘤骨架如复合物相关）。R4.2 的核心科学价值在于其特定的基因缺陷表型——通常表现为抗原提呈相关分子（如 MHC II 类分子转运、加工、或特定的伴侣蛋白如主要组织相容性复合物不变链 Ii / CD74）的缺失或严重下调。在倒置显微镜下，R4.2 细胞呈现出典型的悬浮淋巴母细胞样形态，细胞呈圆形、大小较为均一、常以单个细胞或松散的小细胞簇形式在培养基中悬浮生长。由于该细胞株能够精准阻断特定抗原的胞内加工或 MHC 分子的表面负载通路，它是国际上用于剖析 B 细胞抗原受体（BCR）信号传导、胞内转运内吞动力学、MHC-II 类分子组装排布以及 T-B 细胞相互作用微观分子机制的极其珍贵的变异模型。

二、 细胞培养环境、培养基配方与理化参数

• 标准培养基配方：

  • 基础培养基：BioVector® 改良型 RPMI-1640 液体培养基。

  • 血清添加量：10% 至 15% 优质灭活胎牛血清 (FBS, Fetal Bovine Serum)。注：针对淋巴类细胞，部分亚株使用经 56°C、30分钟热灭菌处理的血清能显著减少补体对悬浮细胞的非特异性损伤。

  • 还原剂（关键添加）：添加终浓度为 50 μM (0.05 mM) 的 β-巯基乙醇 (β-mercaptoethanol)。这是维持小鼠淋巴细胞体外活跃分裂和抗氧化损伤的必需成分。

  • 双抗（可选）：1% 青霉素-链霉素溶液（终浓度 100 U/mL 青霉素，100 μg/mL 链霉素）。

• 理化与物理培养参数：

  • 培养温度：37°C 恒温培养。

  • 气体环境：5% 二氧化碳 ($CO_2$)，饱和空气湿度环境。

  • 密度依赖性：悬浮淋巴细胞对细胞密度高度敏感。培养过程中必须维持其细胞密度在 $2 \times 10^5$ 至 $1 \times 10^6$ cells/mL 之间。过低或过高均会导致细胞大量静息或自发凋亡。

三、 细胞传代、复苏与免疫学实验标准操作步骤

1. 常规悬浮传代操作 (周期 2–3 天)：

   • 悬浮细胞传代无需胰酶消化。当细胞密度达到约 $1 \times 10^6$ cells/mL 且培养基开始轻微变黄时，启动传代。

   • 轻轻摇动培养瓶使细胞分布均匀，吸取全部或部分菌液至无菌离心管中。以每分钟 800 到 1000 转 (RPM) 离心 5 分钟，弃去含代谢废物的旧培养基。

   • 使用新鲜配制的完全培养基（含 FBS 和 β-巯基乙醇）重悬细胞沉淀。按照 1:3 至 1:5 的稀释比例分装至新的培养瓶中，补足培养基体积，置于 37°C 培养箱中继续悬浮孵育。

2. 冻存细胞快速复苏：

   • 从液氮罐中快速取出 R4.2 细胞冻存管，立即投入 37°C 恒温水浴锅中剧烈摇动，使其在 1 分钟左右内完全融化。

   • 用酒精擦拭外壁后，在超净台内将细胞悬液转移至含 5 毫升预热完全培养基的 15 mL 离心管中，1000 RPM 离心 3 分钟以彻底去除冻存剂 DMSO。

   • 弃去上清液，加入 5 毫升新鲜完全培养基重悬，接种至 T25 培养瓶中，于 37°C、5% $CO_2$ 培养箱中过夜。次日观察细胞存活率并计数。

3. 抗原提呈缺失互补实验 (Complementation Assay)：

   • 收集对数生长期的 R4.2 细胞，通过电转（Electroporation）或慢病毒转导（Lentiviral Transduction）将缺失的目标野生型基因（如缺失的伴侣蛋白编码序列）导入 R4.2 细胞中。

   • 筛选获得稳定表达的细胞株后，使用流式细胞术（FACS）检测表面 MHC-II 类分子表达谱的恢复情况。

   • 将其作为提呈细胞（APC），加入特异性抗原肽段并与对应的 T 细胞杂交瘤共培养，通过测定上清中 IL-2 等细胞因子的分泌，来确证抗原提呈通路的分子修复。

四、 细胞株长期保藏与冻存技术

• 标准冻存液配方：现配现用。55% 改良 RPMI-1640 基础培养基 + 35% 优质胎牛血清 (FBS) + 10% 二甲基亚砜 (DMSO)。

• 冷冻降温保藏程序：离心收集处于旺盛对数生长期、活力 $>95\%$ 的 R4.2 细胞。用冷冻保护液轻轻重悬，调节最终细胞密度为每毫升 $3 \times 10^6$ 到 $8 \times 10^6$ 个细胞。分装入无菌冻存管中，放入标准程序降温盒内（确保每分钟降温 1°C），置于零下 80°C 超低温冰箱中过夜。次日必须迅速转入液氮罐（零下 196°C）中进行永久性气相或液相保藏。

五、 质量控制标准与科研应用指南

• 质量控制标准：BioVector® 提供的 R4.2 缺陷型小鼠 B 细胞株通过了极为严苛的质量控制审查。经 PCR 及微生物培养检测确认为 100% 无支原体 (Mycoplasma) 污染，无细菌、真菌及鼠源外源病毒污染；流式细胞术验证其特定的抗原提呈缺陷相关表面标志物核型完全契合其突变株标准；细胞增殖动力学与悬浮特性保持多世代高度稳定。

• 核心实验应用方向：

  • 抗原加工与提呈机制：用于研究内吞外源抗原在胞内如何降解、加工以及如何被负载到 MHC II 类分子结合槽中的精细分子步骤。

  • 小分子伴侣蛋白功能研究：揭示特定的内质网/高尔基体伴侣蛋白或转运小泡在免疫细胞内囊泡运输（Vesicle trafficking）中的生理功能。

  • 免疫受体信号传导：用于 B 细胞受体（BCR）交联后，胞内酪氨酸激酶级联活化、钙离子内流及下游转录因子启动的信号通路剖析。

  • 新型免疫调节药物筛查：用于高通量筛查能够绕过或修复特定抗原提呈缺陷的潜在免疫增强剂、小分子化学靶向药或抗体药物。

PART 2: ENGLISH SECTION

I. General Information and Detailed Product Characterization

• Product Name: BioVector® R4.2 Mutant Mouse B-Cell Lymphoma Line

• Cell Line Name: R4.2

• Species Origin: Mouse (Mus musculus)

• Tissue Source: Derived from a mouse B-cell lymphoma mutant lineage.

• Cell Category: Lymphoblast-like / Suspension growth profile

• Biosafety Level: BSL-1

• Detailed Description: BioVector® R4.2 is a highly specialized, mutant-deficient mouse B-cell lymphoma line that occupies a crucial position in examining immunology, intracellular trafficking, and antigen presentation networks. Developed via targeted physical or chemical mutagenesis of an ancestral B-cell lymphoma background, the primary scientific currency of the R4.2 line rests upon its distinct genetic deficiency phenotype. It typically features a disrupted antigen presentation pathway characterized by the lack or severe down-regulation of functional antigen-processing machinery (such as specific molecular chaperones like the invariant chain Ii / CD74, or defects in appropriate MHC Class II intracellular assembly and egress). Under inverted microscopic observation, R4.2 cells exhibit a standard lymphoblast-like suspension morphology, displaying spherical shapes, uniform dimensions, and growing as single cells or loosely aggregated suspension clusters. By offering a precise structural block in specific vesicle routing or MHC loading cascades, R4.2 serves as an invaluable mutant matrix for delineating B-cell receptor (BCR) signal transduction, endocytic kinetic sorting, MHC-II peptide loading complex assembly, and micro-molecular T-B cell cross-talk.

II. Cultivation Environments, Medium Formulations, and Physical Parameters

• Standardized Growth Medium Formulation:

  • Basal Medium: BioVector® Optimized RPMI-1640 Liquid Medium.

  • Serum Supplementation: 10% to 15% premium heat-inactivated Fetal Bovine Serum (FBS). Note: For suspension lymphoid lines, treating serum at 56°C for 30 minutes is highly strategic to neutralize non-specific complement-mediated lysing of fragile cells.

  • Reducing Agent (Critical Supplement): Supplemented with a definitive final concentration of 50 μM (0.05 mM) β-Mercaptoethanol (β-ME). This element is absolutely mandatory to maintain optimal antioxidant defenses and drive continuous proliferation in murine lymphoid cells in vitro.

  • Antibiotics (Optional): 1% Penicillin-Streptomycin Solution (final concentration of 100 U/mL Penicillin and 100 μg/mL Streptomycin).

• Physical Processing Criteria:

  • Incubation Temperature: Constantly maintained at 37°C.

  • Gaseous Atmosphere: 5% Carbon Dioxide ($CO_2$) balanced with ambient air under saturated humidified conditions.

  • Density Dependency Constraints: Highly sensitive to overcrowding and over-dilution alike. The operating cell density must be strictly regulated to span $2 \times 10^5$ to $1 \times 10^6$ cells/mL. Dropping below or exceeding this narrow window triggers immediate mitotic quiescence or widespread accelerated apoptosis.

III. Subculturing, Cryovial Thawing, and Antigen Complementation Protocols

1. Routine Suspension Passaging Schedule (2–3 Day Routine Loop):

   • Suspension lineages do not require enzymatic disassociation (Trypsinization). Initiate subculturing when cell density approaches approximately $1 \times 10^6$ cells/mL and the phenol red indicator in the medium turns slightly yellow.

   • Agitate the culture vessel gently to ensure an even distribution. Transfer the cell suspension into a sterile tube and centrifuge at 800 to 1000 RPM for 5 minutes. Decant the spent supernatant containing metabolic waste.

   • Resuspend the cell pellet cleanly in fresh complete medium enriched with FBS and β-Mercaptoethanol. Dispense back into new culture flasks at a standard subcultivation split ratio spanning 1:3 to 1:5, and return to the 37°C incubator.

2. Cryopreserved Aliquot Thawing:

   • Retrieve an R4.2 cryovial from the liquid nitrogen storage and immediately submerge it into a 37°C water bath, swirling continuously for approximately 1 minute until the contents liquify completely.

   • Sterilize the vial exterior, transfer the cell solution into a sterile conical tube containing 5 mL of pre-warmed complete medium, and spin at 1000 RPM for 3 minutes to pellet cells and eliminate toxic DMSO protectants.

   • Decant the supernatant, resuspend the cells in fresh complete medium, transfer into a T25 flask, and place inside the 37°C, 5% $CO_2$ incubator overnight. Assess viability and execute a cell count the following day.

3. Antigen Presentation Genetic Complementation Assay:

   • Harvest exponential-phase R4.2 cells and introduce the wild-type counterpart of the mutated gene (e.g., the missing chaperone sequence) via electroporation or lentiviral transduction vectors.

   • Post-selection of stable transfectants, utilize Flow Cytometry (FACS) to screen for the functional restoration of surface MHC Class II peptide complexes.

   • Co-culture the engineered R4.2 variants as Antigen Presenting Cells (APCs) alongside responsive T-cell hybridomas in the presence of targeted exogenous protein antigens. Quantify interleukin-2 (IL-2) secretion in the downstream supernatant via ELISA to validate molecular repair of the antigen processing pathway.

IV. Cell Line Cryopreservation and Long-Term Archiving

• Cryoprotective Matrix Formulation: Formulate freshly before use. 55% optimized RPMI-1640 basal medium + 35% premium Fetal Bovine Serum (FBS) + 10% Dimethyl Sulfoxide (DMSO).

• Rate-Controlled Freezing Schedule: Collect R4.2 suspension cells demonstrating high initial viability ($>95\%$). Resuspend the cell mass gently in chilled cryoprotective matrix, targeting a final concentration spanning $3 \times 10^6$ to $8 \times 10^6$ viable cells per milliliter. Aliquot into sterile cryovials. Enclose vials within a standardized container designed to reduce temperature at a predictable 1°C per minute inside a minus 80°C freezer overnight. Transfer the vials into liquid nitrogen storage (-196°C) the next day for indefinite gas-phase preservation.

V. Quality Control Standards and Strategic Research Applications

• Quality Control Standards: Every batch of BioVector® R4.2 cell lines undergoes rigorous validation profiles. PCR screening certifies 100% negative status for Mycoplasma contamination, alongside absolute freedom from adventitious bacterial, fungal, or murine viral pathogens. Flow cytometry confirms that the specific antigen-presentation surface block remains true to the authentic mutant genotype. Proliferation kinetics and suspension behaviors remain steady across extensive passage windows.

• Core Experimental Applications:

  • Antigen Processing Dynamics: Dissecting the precise biochemical steps governing how exogenous proteins are internalized, degraded in endolysosomal vesicles, and loaded into the cleft of MHC Class II molecules.

  • Molecular Chaperone Functional Mapping: Unveiling the precise regulatory role of ER/Golgi chaperones and transport vesicles during intracellular vesicle trafficking within immune subsets.

  • Immune Receptor Cascade Tracking: Profiling downstream tyrosine kinase activation, intracellular calcium flux, and transcription factor nuclear translocation following B-cell receptor (BCR) cross-linking.

  • Immunomodulatory Drug Screening: Serving as an exceptional targeted assay matrix for high-throughput discovery of small molecules, targeted biologics, or chemical enhancers capable of bypassing or correcting specific antigen presentation Blocks.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net